Botulinum neurotoxins (BoNT) are produced by Clostridium botulinum and cause severe neuroparalytic disease that if not treated quickly is often fatal. The toxin is produced as a 150 kDa precursor protein (holotoxin) that is enzymatically cleaved to form two subunits, heavy and light chains, linked by a single disulfide bond. Seven toxin serotypes are known. BoNT serotypes A1 and B1 are secreted as precursor toxic complexes (PTC) containing of the toxin and non-toxic associated proteins (NAPs) consisting of non-toxic hemagglutinin proteins (HA), designated HA17, HA34, and HA70, and a 120 kDa non-toxin non-hemagglutinin (NTNH) protein. The exact contribution of the NAPs in disease is not known, but it is thought that they protect the toxin as it passes through the harsh environment of the stomach. The structure of the complex is also poorly understood, although recent models suggest that for each molecule of toxin the PTC contains one molecule of the NTNH and multiple copies of each HA. In this paper we describe six monoclonal antibodies that specifically bind the HA70 protein found in the PTC of BoNT/A1 and /B1. Based on these antibodies, we demonstrate a rapid sandwich ELISA assay for detecting HA70.

Download full-text PDF

Source
http://dx.doi.org/10.1089/mab.2012.0071DOI Listing

Publication Analysis

Top Keywords

monoclonal antibodies
8
clostridium botulinum
8
sandwich elisa
8
toxin
5
development characterization
4
characterization monoclonal
4
antibodies hemagglutinin-70
4
hemagglutinin-70 clostridium
4
botulinum application
4
application sandwich
4

Similar Publications

Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.

View Article and Find Full Text PDF

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

Sci Rep

January 2025

Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.

Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.

View Article and Find Full Text PDF

To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma (uHCC). The clinical data of 64 patients with unresectable HCC, who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023, were retrospectively analyzed. The patients were divided into a combination group (=43, receiving TACE combined with sintilimab and bevacizumab biosimilar) and control group (=21, receiving only sintilimab and bevacizumab biosimilar).

View Article and Find Full Text PDF

Background: Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.

View Article and Find Full Text PDF

Background: B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 across various solid tumors and developed novel monoclonal antibodies (mAbs) targeting B7-H3 for CAR T cell therapy.

Methods: Expression of B7-H3 across various solid tumors was evaluated using RNA-seq data from TCGA, TARGET, and GTEx datasets and by flow cytometry staining.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!